| 1.503 -0.017 (-1.12%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.93 | 1-year : | 2.16 |
| Resists | First : | 1.65 | Second : | 1.85 |
| Pivot price | 1.53  |
|||
| Supports | First : | 1.35 | Second : | 1.12 |
| MAs | MA(5) : | 1.49  |
MA(20) : | 1.58 |
| MA(100) : | 1.79 |
MA(250) : | 2.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.2 |
D(3) : | 36.2 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 5 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AEMD ] has closed above bottom band by 42.1%. Bollinger Bands are 19.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Thu, 15 Feb 2024
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript - Yahoo Finance
Wed, 14 Feb 2024
Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript - Seeking Alpha
Fri, 24 Nov 2023
Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Aethlon - Benzinga
Mon, 13 Nov 2023
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy ... - PR Newswire
Thu, 05 Oct 2023
Aethlon Medical (NASDAQ: AEMD) to jump 1,000% - no, don’t, really - Dhaka Tribune
Mon, 02 Aug 2021
Aethlon Medical, Inc. (AEMD) has gained 3.47% Monday In Premarket Trading - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.41e+006 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.14e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 47.1 % |
| Return on Equity (ttm) | -47.2 % |
| Qtrly Rev. Growth | 574250 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -50.74 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.99 |
| Dividend | 0 |
| Forward Dividend | 18920 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|